Podcasts about ifx

Play Episode Listen Later Jul 22, 2020

Host: Abdullah Abdussalam, MD Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Diana M Negoescu, Eva A Enns, PhD, Brooke Swanhorst, Bonnie Baumgartner, James P Campbell, Mark T Osterman, MD, Konstantinos Papamichael, PhD, Adam S Cheifetz, MD, Byron P Vaughn, MD Background: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of proactive vs reactive TDM in a simulated population of CD patients on IFX. Methods: We developed a stochastic simulation model of CD patients on IFX and evaluated the expected health costs and outcomes of a proactive TDM strategy compared with a reactive strategy. The proactive strategy measured IFX concentration and antibody status every 6 months, or at the time of a flare, and dosed IFX to a therapeutic window. The reactive strategy only did so at the time of a flare.

phd nutrition md disease cd drug monitoring proactive therapeutic crohn reactive rmd clinical pharmacology tdm reachmd general medicine and primary care infliximab gastroenterology and hepatology ifx audioabstracts gi insights

Proactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease

Play Episode Listen Later Jul 22, 2020

Host: Abdullah Abdussalam, MD Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Diana M Negoescu, Eva A Enns, PhD, Brooke Swanhorst, Bonnie Baumgartner, James P Campbell, Mark T Osterman, MD, Konstantinos Papamichael, PhD, Adam S Cheifetz, MD, Byron P Vaughn, MD Background: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of proactive vs reactive TDM in a simulated population of CD patients on IFX. Methods: We developed a stochastic simulation model of CD patients on IFX and evaluated the expected health costs and outcomes of a proactive TDM strategy compared with a reactive strategy. The proactive strategy measured IFX concentration and antibody status every 6 months, or at the time of a flare, and dosed IFX to a therapeutic window. The reactive strategy only did so at the time of a flare.

phd nutrition md disease cd drug monitoring proactive therapeutic crohn reactive rmd clinical pharmacology tdm reachmd general medicine and primary care infliximab gastroenterology and hepatology ifx audioabstracts gi insights

Proactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease

Play Episode Listen Later Jul 22, 2020

Host: Abdullah Abdussalam, MD Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Diana M Negoescu, Eva A Enns, PhD, Brooke Swanhorst, Bonnie Baumgartner, James P Campbell, Mark T Osterman, MD, Konstantinos Papamichael, PhD, Adam S Cheifetz, MD, Byron P Vaughn, MD Background: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of proactive vs reactive TDM in a simulated population of CD patients on IFX. Methods: We developed a stochastic simulation model of CD patients on IFX and evaluated the expected health costs and outcomes of a proactive TDM strategy compared with a reactive strategy. The proactive strategy measured IFX concentration and antibody status every 6 months, or at the time of a flare, and dosed IFX to a therapeutic window. The reactive strategy only did so at the time of a flare.

phd nutrition md disease cd drug monitoring proactive therapeutic crohn reactive rmd clinical pharmacology tdm reachmd general medicine and primary care infliximab gastroenterology and hepatology ifx audioabstracts gi insights

Proactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease

Play Episode Listen Later Jul 22, 2020

Host: Abdullah Abdussalam, MD Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Diana M Negoescu, Eva A Enns, PhD, Brooke Swanhorst, Bonnie Baumgartner, James P Campbell, Mark T Osterman, MD, Konstantinos Papamichael, PhD, Adam S Cheifetz, MD, Byron P Vaughn, MD Background: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of proactive vs reactive TDM in a simulated population of CD patients on IFX. Methods: We developed a stochastic simulation model of CD patients on IFX and evaluated the expected health costs and outcomes of a proactive TDM strategy compared with a reactive strategy. The proactive strategy measured IFX concentration and antibody status every 6 months, or at the time of a flare, and dosed IFX to a therapeutic window. The reactive strategy only did so at the time of a flare.

phd nutrition md disease cd drug monitoring proactive therapeutic crohn reactive rmd clinical pharmacology tdm reachmd general medicine and primary care infliximab gastroenterology and hepatology ifx audioabstracts gi insights

Proactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease

Play Episode Listen Later Jul 22, 2020

Host: Abdullah Abdussalam, MD Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Diana M Negoescu, Eva A Enns, PhD, Brooke Swanhorst, Bonnie Baumgartner, James P Campbell, Mark T Osterman, MD, Konstantinos Papamichael, PhD, Adam S Cheifetz, MD, Byron P Vaughn, MD Background: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of proactive vs reactive TDM in a simulated population of CD patients on IFX. Methods: We developed a stochastic simulation model of CD patients on IFX and evaluated the expected health costs and outcomes of a proactive TDM strategy compared with a reactive strategy. The proactive strategy measured IFX concentration and antibody status every 6 months, or at the time of a flare, and dosed IFX to a therapeutic window. The reactive strategy only did so at the time of a flare.

phd nutrition md disease cd drug monitoring proactive therapeutic crohn reactive rmd clinical pharmacology tdm reachmd general medicine and primary care infliximab gastroenterology and hepatology ifx audioabstracts gi insights

Proactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease

Jefferies EMEA Market Minutes

Play Episode Listen Later Jul 22, 2020

Host: Abdullah Abdussalam, MD Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Diana M Negoescu, Eva A Enns, PhD, Brooke Swanhorst, Bonnie Baumgartner, James P Campbell, Mark T Osterman, MD, Konstantinos Papamichael, PhD, Adam S Cheifetz, MD, Byron P Vaughn, MD Background: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of proactive vs reactive TDM in a simulated population of CD patients on IFX. Methods: We developed a stochastic simulation model of CD patients on IFX and evaluated the expected health costs and outcomes of a proactive TDM strategy compared with a reactive strategy. The proactive strategy measured IFX concentration and antibody status every 6 months, or at the time of a flare, and dosed IFX to a therapeutic window. The reactive strategy only did so at the time of a flare.

phd nutrition md disease cd drug monitoring proactive therapeutic crohn reactive rmd clinical pharmacology tdm reachmd general medicine and primary care infliximab gastroenterology and hepatology ifx audioabstracts gi insights

Friday 17th July - Europe UNCH

Play Episode Listen Later Jul 17, 2020 4:39

• Europe is unch on the day, volumes are fairly muted as well • The EU meeting on the Recovery Fund started today at 9am London time. We could potentially start seeing some headlines in the afternoon over the possible disagreement points. There is also a press conference scheduled in the evening, likely after market close. Market expectations from the summit are low with the central scenario being that another summit needs to be scheduled towards end July/beginning August. • STERLING weakness continues trading below €1.10 more press spec. expectations that UK BOE will cut rates by 10bps at next meeting. • BoE Governor Bailey is speaking at 11am London time and any comments around negative rates being off the table would be closely watched. • Unlike in the US overnight Tech is +1% outperforming ... • Ericsson +10% as the cos second quater Results tops ests + Maintains FY20 & FY22 targets. helping sentiment acorss the sector STM +3%, IFX +2.5% • Auto's +1.6% vol's +50% driven by Daimler +4.5% post earnings • ASSA ABLOY -2% from opening +4% post +ve earnings also Wartsila -1% having opened +7% also doing the same

europe tech european union market auto results ericsson daimler stm recovery fund assa abloy ifx

Mitch Moroney Show #2 - Kerrin Simmonds Full

institute gm general managers ipa simmonds moroney membership development public accountants ifx

Play Episode Listen Later May 28, 2020 59:15

Mitch welcomes Kerrin Simmonds in today's episode. Kerrin has been General Manager of the Institute of Public Accountants for the last 6 years. Prior to the GM position, she worked as Membership Development and Growth Executive for 12 months. Kerrin has a wide variety of experience in the financial industry, starting as a Junior Teller at Bank West at the age of 18 through to being a PA and event planner in various accounting and law-based organizations. Kerrin joins Mitch to discuss her career path and what she has learned from each position. She also discusses how she fits being a mother into her busy work life. Stay tuned to hear about: Kerrin's experience working at Bank West Moving to the IT department and what that involves at a bank The requirements for being a financial advisor in the past vs. now The impact the change on requirements has had on people that have been in business for years Fostering an experience with clients over selling a product for the sake of it How the IPA strives to foster community over being just an organization The partnership between the IPA and the IFX and its benefits for members The importance of prior accounts knowledge before opening a business Mum guilt and how it has affected her How the collapse of the mining boom affected the IPA operations Accepting short term pain for long term gain What Kerrin learned from setting up international events Mitch finishes the podcast by asking Kerrin a quick 5 questions: What are the most important qualities in business? What superpower would you have? What advice would you give your younger self? Who's your favourite footie team? What is your favourite book? The Institute of Public Accountants Kerrin Simmonds LinkedIn

Mitch Moroney Show #2 - Kerrin Simmonds Part 3

institute gm general managers ipa simmonds moroney membership development public accountants ifx

Play Episode Listen Later May 27, 2020 17:21

Mitch welcomes Kerrin Simmonds in today's episode. Kerrin has been General Manager of the Institute of Public Accountants for the last 6 years. Prior to the GM position, she worked as Membership Development and Growth Executive for 12 months. Kerrin has a wide variety of experience in the financial industry, starting as a Junior Teller at Bank West at the age of 18 through to being a PA and event planner in various accounting and law-based organizations. Kerrin joins Mitch to discuss her career path and what she has learned from each position. She also discusses how she fits being a mother into her busy work life. Stay tuned to hear about: Kerrin's experience working at Bank West Moving to the IT department and what that involves at a bank The requirements for being a financial advisor in the past vs. now The impact the change on requirements has had on people that have been in business for years Fostering an experience with clients over selling a product for the sake of it How the IPA strives to foster community over being just an organization The partnership between the IPA and the IFX and its benefits for members The importance of prior accounts knowledge before opening a business Mum guilt and how it has affected her How the collapse of the mining boom affected the IPA operations Accepting short term pain for long term gain What Kerrin learned from setting up international events Mitch finishes the podcast by asking Kerrin a quick 5 questions: What are the most important qualities in business? What superpower would you have? What advice would you give your younger self? Who's your favourite footie team? What is your favourite book? The Institute of Public Accountants Kerrin Simmonds LinkedIn

Mitch Moroney Show #2 - Kerrin Simmonds Part 2

institute gm general managers ipa simmonds moroney membership development public accountants ifx

Play Episode Listen Later May 26, 2020 19:04

Mitch welcomes Kerrin Simmonds in today's episode. Kerrin has been General Manager of the Institute of Public Accountants for the last 6 years. Prior to the GM position, she worked as Membership Development and Growth Executive for 12 months. Kerrin has a wide variety of experience in the financial industry, starting as a Junior Teller at Bank West at the age of 18 through to being a PA and event planner in various accounting and law-based organizations. Kerrin joins Mitch to discuss her career path and what she has learned from each position. She also discusses how she fits being a mother into her busy work life. Stay tuned to hear about: Kerrin's experience working at Bank West Moving to the IT department and what that involves at a bank The requirements for being a financial advisor in the past vs. now The impact the change on requirements has had on people that have been in business for years Fostering an experience with clients over selling a product for the sake of it How the IPA strives to foster community over being just an organization The partnership between the IPA and the IFX and its benefits for members The importance of prior accounts knowledge before opening a business Mum guilt and how it has affected her How the collapse of the mining boom affected the IPA operations Accepting short term pain for long term gain What Kerrin learned from setting up international events Mitch finishes the podcast by asking Kerrin a quick 5 questions: What are the most important qualities in business? What superpower would you have? What advice would you give your younger self? Who's your favourite footie team? What is your favourite book? The Institute of Public Accountants Kerrin Simmonds LinkedIn

Mitch Moroney Show #2 - Kerrin Simmonds Part 1

institute gm general managers ipa simmonds moroney membership development public accountants ifx

Play Episode Listen Later May 25, 2020 23:24

Mitch welcomes Kerrin Simmonds in today's episode. Kerrin has been General Manager of the Institute of Public Accountants for the last 6 years. Prior to the GM position, she worked as Membership Development and Growth Executive for 12 months. Kerrin has a wide variety of experience in the financial industry, starting as a Junior Teller at Bank West at the age of 18 through to being a PA and event planner in various accounting and law-based organizations. Kerrin joins Mitch to discuss her career path and what she has learned from each position. She also discusses how she fits being a mother into her busy work life. Stay tuned to hear about: Kerrin's experience working at Bank West Moving to the IT department and what that involves at a bank The requirements for being a financial advisor in the past vs. now The impact the change on requirements has had on people that have been in business for years Fostering an experience with clients over selling a product for the sake of it How the IPA strives to foster community over being just an organization The partnership between the IPA and the IFX and its benefits for members The importance of prior accounts knowledge before opening a business Mum guilt and how it has affected her How the collapse of the mining boom affected the IPA operations Accepting short term pain for long term gain What Kerrin learned from setting up international events Mitch finishes the podcast by asking Kerrin a quick 5 questions: What are the most important qualities in business? What superpower would you have? What advice would you give your younger self? Who's your favourite footie team? What is your favourite book? The Institute of Public Accountants Kerrin Simmonds LinkedIn

Developers Are Putting Pressure on Infrastructure Teams to Modernize

The New Stack Podcast

Play Episode Listen Later Dec 24, 2019 30:01

The New Stack Founder and Publisher Alex Williams sat down at the IFX infrastructure conference with one of the companies looking to apply the speed, delivery, and, most importantly, the resilience built into software teams to the infrastructure side. After over a decade at Microsoft followed by more than a year at AWS, Luke Hoban, CTO of Pulumi, was ready to build something that helps developers work with the cloud. The way to bridge the chasm and bring the application development and infrastructure on either side closer together.

microsoft putting pressure infrastructure developers cto aws modernize ifx

Developers Are Putting Pressure on Infrastructure Teams to Modernize

The New Stack Context

Play Episode Listen Later Dec 23, 2019 30:00

The New Stack Editor in Chief Alex Williams sat down at the IFX infrastructure conference with one of the companies looking to apply the speed, delivery, and, most importantly, the resilience built into software teams to the infrastructure side. After over a decade at Microsoft followed by more than a year at AWS, Luke Hoban, CTO of Pulumi, was ready to build something that helps developers work with the cloud. The way to bridge the chasm and bring the application development and infrastructure on either side closer together.

microsoft putting pressure infrastructure developers cto aws modernize ifx

Context Episode 95: AWS Re:Invent, IFX

The New Stack Context

Play Episode Listen Later Dec 6, 2019 22:10

In Context Episode #95 The New Stack Crew discusses two conferences this week: Amazon Web Services' RE:Invent 2019 and Packet's IFX conference. TNS Publisher Alex Williams hosted this episode, and we speak with TNS European Correspondent B. Cameron Gain. This episode was sponsored by CloudBees.

context reinvent amazon web services packet cloudbees ifx

Context Episode 95: AWS Re:Invent, IFX

The New Stack Podcast

Play Episode Listen Later Dec 6, 2019 22:10

In Context Episode #95 The New Stack Crew discusses two conferences this week: Amazon Web Services' RE:Invent 2019 and Packet's IFX conference. TNS Publisher Alex Williams hosted this episode, and we speak with TNS European Correspondent B. Cameron Gain. This episode was sponsored by CloudBees.

context reinvent amazon web services packet cloudbees ifx

Assessing the Correlation Between Perianal Fistula Healing & Trough Levels of Infliximab in Children with IBD

Play Episode Listen Later Jun 19, 2019

Host: Alka Goyal, MD Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children. Wael El-Matary, MD, MSc Thomas D Walters, MD Hien Q Huynh, MDJennifer deBruyn, MD David R Mack, MD Kevan Jacobson, MD Mary E Sherlock, MDPeter Church, MD Eytan Wine, MD, PhD Matthew W Carroll, MD, Eric I Benchimol, MD, PhD Sally Lawrence, MD Anne M Griffiths, MD Background: There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24. Methods: In a multicenter inception cohort study, consecutive children younger than age 17 years with fistulizing perianal CD treated with IFX between April 2014 and June 2017 who had serum trough IFX titers measured before the fourth infusion were included. Area under the receiver operating characteristic curve (AUROC) was calculated to determine the best cutoff to predict fistula ...

children healing md disease cd levels assessing pediatrics crohn correlation trough rmd fistula reachmd infliximab gastroenterology and hepatology ifx audioabstracts auroc gi insights cd pcd fistulizing perianal crohn

Assessing the Correlation Between Perianal Fistula Healing & Trough Levels of Infliximab in Children with IBD

Play Episode Listen Later Jun 19, 2019

Host: Alka Goyal, MD Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children. Wael El-Matary, MD, MSc Thomas D Walters, MD Hien Q Huynh, MDJennifer deBruyn, MD David R Mack, MD Kevan Jacobson, MD Mary E Sherlock, MDPeter Church, MD Eytan Wine, MD, PhD Matthew W Carroll, MD, Eric I Benchimol, MD, PhD Sally Lawrence, MD Anne M Griffiths, MD Background: There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24. Methods: In a multicenter inception cohort study, consecutive children younger than age 17 years with fistulizing perianal CD treated with IFX between April 2014 and June 2017 who had serum trough IFX titers measured before the fourth infusion were included. Area under the receiver operating characteristic curve (AUROC) was calculated to determine the best cutoff to predict fistula ...

children healing md disease cd levels assessing pediatrics crohn correlation trough rmd fistula reachmd infliximab gastroenterology and hepatology ifx audioabstracts auroc gi insights cd pcd fistulizing perianal crohn

Assessing the Correlation Between Perianal Fistula Healing & Trough Levels of Infliximab in Children with IBD

Play Episode Listen Later Jun 19, 2019

Host: Alka Goyal, MD Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children. Wael El-Matary, MD, MSc Thomas D Walters, MD Hien Q Huynh, MDJennifer deBruyn, MD David R Mack, MD Kevan Jacobson, MD Mary E Sherlock, MDPeter Church, MD Eytan Wine, MD, PhD Matthew W Carroll, MD, Eric I Benchimol, MD, PhD Sally Lawrence, MD Anne M Griffiths, MD Background: There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24. Methods: In a multicenter inception cohort study, consecutive children younger than age 17 years with fistulizing perianal CD treated with IFX between April 2014 and June 2017 who had serum trough IFX titers measured before the fourth infusion were included. Area under the receiver operating characteristic curve (AUROC) was calculated to determine the best cutoff to predict fistula ...

children healing md disease cd levels assessing pediatrics crohn correlation trough rmd fistula reachmd infliximab gastroenterology and hepatology ifx audioabstracts auroc gi insights cd pcd fistulizing perianal crohn

Assessing the Correlation Between Perianal Fistula Healing & Trough Levels of Infliximab in Children with IBD

Focus on Children's Health

Play Episode Listen Later Jun 18, 2019

Host: Alka Goyal, MD Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children. Wael El-Matary, MD, MSc Thomas D Walters, MD Hien Q Huynh, MDJennifer deBruyn, MD David R Mack, MD Kevan Jacobson, MD Mary E Sherlock, MDPeter Church, MD Eytan Wine, MD, PhD Matthew W Carroll, MD, Eric I Benchimol, MD, PhD Sally Lawrence, MD Anne M Griffiths, MD Background: There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24. Methods: In a multicenter inception cohort study, consecutive children younger than age 17 years with fistulizing perianal CD treated with IFX between April 2014 and June 2017 who had serum trough IFX titers measured before the fourth infusion were included. Area under the receiver operating characteristic curve (AUROC) was calculated to determine the best cutoff to predict fistula ...

children healing md disease cd levels assessing pediatrics crohn correlation trough rmd fistula reachmd infliximab gastroenterology and hepatology ifx focus on children's health audioabstracts auroc gi insights cd pcd fistulizing perianal crohn

Assessing the Correlation Between Perianal Fistula Healing & Trough Levels of Infliximab in Children with IBD

Play Episode Listen Later Jun 18, 2019

Host: Alka Goyal, MD Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children. Wael El-Matary, MD, MSc Thomas D Walters, MD Hien Q Huynh, MDJennifer deBruyn, MD David R Mack, MD Kevan Jacobson, MD Mary E Sherlock, MDPeter Church, MD Eytan Wine, MD, PhD Matthew W Carroll, MD, Eric I Benchimol, MD, PhD Sally Lawrence, MD Anne M Griffiths, MD Background: There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24. Methods: In a multicenter inception cohort study, consecutive children younger than age 17 years with fistulizing perianal CD treated with IFX between April 2014 and June 2017 who had serum trough IFX titers measured before the fourth infusion were included. Area under the receiver operating characteristic curve (AUROC) was calculated to determine the best cutoff to predict fistula ...

children healing md disease cd levels assessing pediatrics crohn correlation trough rmd fistula reachmd infliximab gastroenterology and hepatology ifx focus on children's health audioabstracts auroc gi insights cd pcd fistulizing perianal crohn

Assessing the Correlation Between Perianal Fistula Healing & Trough Levels of Infliximab in Children with IBD

Play Episode Listen Later Jun 18, 2019

Host: Alka Goyal, MD Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children. Wael El-Matary, MD, MSc Thomas D Walters, MD Hien Q Huynh, MDJennifer deBruyn, MD David R Mack, MD Kevan Jacobson, MD Mary E Sherlock, MDPeter Church, MD Eytan Wine, MD, PhD Matthew W Carroll, MD, Eric I Benchimol, MD, PhD Sally Lawrence, MD Anne M Griffiths, MD Background: There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24. Methods: In a multicenter inception cohort study, consecutive children younger than age 17 years with fistulizing perianal CD treated with IFX between April 2014 and June 2017 who had serum trough IFX titers measured before the fourth infusion were included. Area under the receiver operating characteristic curve (AUROC) was calculated to determine the best cutoff to predict fistula ...

children healing md disease cd levels assessing pediatrics crohn correlation trough rmd fistula reachmd infliximab gastroenterology and hepatology ifx focus on children's health audioabstracts auroc gi insights cd pcd fistulizing perianal crohn

Assessing the Correlation Between Perianal Fistula Healing & Trough Levels of Infliximab in Children with IBD

ceo founders germany international xchange mike carlson michael carlson ifx

Play Episode Listen Later Jun 18, 2019

Host: Alka Goyal, MD Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children. Wael El-Matary, MD, MSc Thomas D Walters, MD Hien Q Huynh, MDJennifer deBruyn, MD David R Mack, MD Kevan Jacobson, MD Mary E Sherlock, MDPeter Church, MD Eytan Wine, MD, PhD Matthew W Carroll, MD, Eric I Benchimol, MD, PhD Sally Lawrence, MD Anne M Griffiths, MD Background: There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24. Methods: In a multicenter inception cohort study, consecutive children younger than age 17 years with fistulizing perianal CD treated with IFX between April 2014 and June 2017 who had serum trough IFX titers measured before the fourth infusion were included. Area under the receiver operating characteristic curve (AUROC) was calculated to determine the best cutoff to predict fistula ...

children healing md disease cd levels assessing pediatrics crohn correlation trough rmd fistula reachmd infliximab gastroenterology and hepatology ifx focus on children's health audioabstracts auroc gi insights cd pcd fistulizing perianal crohn

Mike Carlson - Founder and CEO of International Fútbol X-Change

Full 90 Coaching

Play Episode Listen Later Mar 11, 2019 41:36

Michael Carlson is the Founder and CEO of International Futbol X-Change. In today’s discussion, Mike shares his own experience of playing soccer abroad while in Germany and how it sparked the idea for him to start IFX 16 years ago. We dive into the different programs offered by IFX and how we provide ongoing support to our players during their journey. How to Contact Mike: Phone: 510-599-4625 Email: info@ifxsoccer.com Coach Ted’s Scouting Email Ted.steen@ifxsoccer.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/full90coaching/support

Coach Ted Talks Tuesdays! Life as a Scout

Full 90 Coaching

Play Episode Listen Later Jan 29, 2019 7:37

Today, I discussed my role as a Scout, both for Diablo Valley College Women’s Soccer and for International Futbol X-Change (IFX). Learn what coaches are looking for and the many options available to players of all ages, genders, and abilities. Players interested in attending DVC and playing for the Vikings should visit: www.dvcvikings.com Players interested in participating in one of the many International playing opportunities provided by IFX should send me an email: ted.steen@ifxsoccer.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/full90coaching/support

coach international players soccer vikings ted talks dvc ifx

Solving the Problem of Inflammation with Dr. Niels Riedemann InflaRx

Empowered Patient Podcast

Play Episode Listen Later Sep 4, 2018 18:34

Dr. Niels Riedemann, Co-founder and CEO of InflaRx, discusses the pervasive problem of inflammation in a host of diseases, and how InflaRx is tackling this problem with their clinical-stage antibody therapy, IFX-1. InflaRx believes that they have found the key to addressing inflammation across a range of diseases, in the form of a molecule in the blood, complement factor C5a. Their main focus is on using IFX-1, a monoclonal antibody, to block C5a and prevent its action in patients with hidradenitis suppurativa (HS), a devastating autoimmune disorder that manifests on the skin, to reduce inflammatory lesions and potentially prove an ability of IFX-1 to work in different inflammatory conditions. #inflammation #InflaRx #complementsystem #HS #immunology #IFX1 InflaRx.com

ceo inflammation hs niels ifx

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance

Play Episode Listen Later Jan 2, 2018

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance. Liefferinckx C1, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D. BACKGROUND: Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss of response (LOR) to IFX is reported in up to 10% to 30% of patients within the first year of treatment. Our objective was to evaluate the impact of the pharmacokinetics of IFX at induction on treatment failure. METHODS: This is a longitudinal cohort study on 269 patients with IBD treated with IFX in a single center. A total of 2331 blood samples were prospectively collected from 2007 until March 2015 with a retrospective analysis of clinical data. IFX trough levels (TLs) were measured by enzyme-linked immunosorbent assay. Antibodies to IFX were measured by drug-sensitive bridging assay. RESULTS: During follow-up, patients were defined according to treatment outcome. At week 6, median IFX TL in patients requiring a switch to another treatment due to LOR (LOR switched group) (2.32 μg/mL [0.12-19.93 μg/mL]) was lower than in patients with long-term response (long-term responders) (8.66 μg/mL [0.12-12.09 μg/mL], P = ...

failure treatments levels maintenance predict ml antibodies ibd l'or medical research tls trough rmd reachmd general medicine and primary care infliximab gastroenterology and hepatology ifx audioabstracts results during

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance

Play Episode Listen Later Jan 2, 2018

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance. Liefferinckx C1, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D. BACKGROUND: Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss of response (LOR) to IFX is reported in up to 10% to 30% of patients within the first year of treatment. Our objective was to evaluate the impact of the pharmacokinetics of IFX at induction on treatment failure. METHODS: This is a longitudinal cohort study on 269 patients with IBD treated with IFX in a single center. A total of 2331 blood samples were prospectively collected from 2007 until March 2015 with a retrospective analysis of clinical data. IFX trough levels (TLs) were measured by enzyme-linked immunosorbent assay. Antibodies to IFX were measured by drug-sensitive bridging assay. RESULTS: During follow-up, patients were defined according to treatment outcome. At week 6, median IFX TL in patients requiring a switch to another treatment due to LOR (LOR switched group) (2.32 μg/mL [0.12-19.93 μg/mL]) was lower than in patients with long-term response (long-term responders) (8.66 μg/mL [0.12-12.09 μg/mL], P = ...

failure treatments levels maintenance predict ml antibodies ibd l'or medical research tls trough rmd reachmd general medicine and primary care infliximab gastroenterology and hepatology ifx audioabstracts results during

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance

Play Episode Listen Later Jan 1, 2018

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance. Liefferinckx C1, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D. BACKGROUND: Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss of response (LOR) to IFX is reported in up to 10% to 30% of patients within the first year of treatment. Our objective was to evaluate the impact of the pharmacokinetics of IFX at induction on treatment failure. METHODS: This is a longitudinal cohort study on 269 patients with IBD treated with IFX in a single center. A total of 2331 blood samples were prospectively collected from 2007 until March 2015 with a retrospective analysis of clinical data. IFX trough levels (TLs) were measured by enzyme-linked immunosorbent assay. Antibodies to IFX were measured by drug-sensitive bridging assay. RESULTS: During follow-up, patients were defined according to treatment outcome. At week 6, median IFX TL in patients requiring a switch to another treatment due to LOR (LOR switched group) (2.32 μg/mL [0.12-19.93 μg/mL]) was lower than in patients with long-term response (long-term responders) (8.66 μg/mL [0.12-12.09 μg/mL], P = ...

failure treatments levels maintenance predict ml antibodies ibd l'or medical research tls trough rmd reachmd general medicine and primary care infliximab gastroenterology and hepatology ifx audioabstracts results during

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance